KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections[1].
Molecular Weight:
932.30
Formula:
C39H34ClF8N7O5S2
Target:
HIV
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
